Ronald F van Vollenhoven
Overview
Explore the profile of Ronald F van Vollenhoven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
242
Citations
10931
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary
Werth V, Furie R, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven R, et al.
Immunotherapy
. 2025 Feb;
:1-13.
PMID: 39995069
No abstract available.
2.
Furie R, van Vollenhoven R, Kalunian K, Navarra S, Romero-Diaz J, Werth V, et al.
Immunotherapy
. 2025 Feb;
:1-13.
PMID: 39995062
No abstract available.
3.
Frazzei G, Landewe R, Wagenaar C, van de Stadt L, van Schaardenburg D, Tas S, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39956700
Objectives: The aim of this study was to predict rheumatoid arthritis (RA) development in a cohort of at-risk individuals with arthralgia positive for anti-citrullinated protein antibodies (ACPA) and/or rheumatoid factor...
4.
5.
Dijkshoorn B, Hansildaar R, Vedder D, Soutari N, Rudin A, Nordstrom D, et al.
RMD Open
. 2024 Dec;
10(4.
PMID: 39740931
Objectives: To assess the effect of treatment on haemostatic parameters in patients with early rheumatoid arthritis (RA). Methods: Patients with newly diagnosed RA started methotrexate and were randomised to additional...
6.
Frazzei G, Cramer S, Landewe R, Maijer K, Gerlag D, Tak P, et al.
RMD Open
. 2024 Oct;
10(4).
PMID: 39424405
Objectives: Early treatment of individuals at risk of developing rheumatoid arthritis (RA-risk) in the preclinical phase has the potential to positively impact both patients and society by preventing disease onset...
7.
Lend K, Lampa J, Padyukov L, Hetland M, Heiberg M, Nordstrom D, et al.
Ann Rheum Dis
. 2024 Jul;
83(12):1657-1665.
PMID: 39079894
Objectives: To investigate whether rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs) and shared epitope (SE) allele-related genetic markers associate with treatment response to abatacept, certolizumab pegol or tocilizumab versus active...
8.
van Vollenhoven R, Hall S, Wells A, Meerwein S, Song Y, Tanjinatus O, et al.
RMD Open
. 2024 Jul;
10(3.
PMID: 39053948
Objective: To evaluate the long-term sustainability of response to the Janus kinase inhibitor upadacitinib among patients with rheumatoid arthritis and an inadequate response or intolerance to biological disease-modifying antirheumatic drugs...
9.
Hellamand P, van de Sande M, Nurmohamed M, van Vollenhoven R, Hollick R, Rotariu O, et al.
Rheumatology (Oxford)
. 2024 Jul;
PMID: 39041780
Objectives: To investigate sex differences in patient-reported outcome measures (PROMs) among axSpA patients initiating their first TNFi and identify factors contributing to these disparities over the follow-up. Methods: Data were...
10.
Parra Sanchez A, van Vollenhoven R, Morand E, Bruce I, Kandane-Rathnayake R, Weiss G, et al.
Rheumatol Ther
. 2024 Jun;
11(4):1059-1061.
PMID: 38847996
No abstract available.